Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases

Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone payment
... | March 28, 2023

Related Keywords

United States ,Sonoma Bio ,Georged Yancopoulos ,Sonoma Biotherapeutic ,Sonoma Biotherapeutics ,Regeneron Velocisuite ,Sonoma Biotherapeutics Inc ,Regeneron Pharmaceuticals Inc ,Twitter ,Nasdaq ,Linkedin ,Regeneron Genetics Center ,Regeneron Pharmaceuticals ,Jeff Bluestone ,Chief Executive Officer ,Chief Scientific Officer ,South San Francisco ,Forward Looking Statements ,Product Candidates ,Nc Stock Exchange ,News ,Information ,Press Release ,Sonoma ,Iotherapeutics ,O ,Eceive ,Billion ,Inclusive ,F ,Cash ,End ,Equity ,Potential ,Or ,N ,Dditional ,Development ,Ilestone Regn Us75886f1075 ,